Etaracizumab

From Self-sufficiency
Jump to: navigation, search
Etaracizumab
Monoclonal antibody
Type Whole antibody
Source Template:Infobox drug/mab source
Target alpha-v beta-3 integrin
Identifiers
CAS Number 892553-42-3
ATC code none
Chemical data
Formula C6392H9908N1732O1996S42
Molar mass 144.3 kDa[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Etaracizumab (also known as etaratuzumab[citation needed], MEDI-522, trade name Abegrin) is a humanized monoclonal antibody which is being investigated for the treatment of metastatic melanoma, prostate cancer[1], ovarian cancer[2] and various other types of cancer.[3] It is manufactured by MedImmune.[1]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


  1. 1.0 1.1 Statement On A Nonproprietary Name Adopted By The Usan Council: Etaracizumab
  2. Landen, CN; Kim, TJ; Lin, YG; Merritt, WM; Kamat, AA; Han, LY; Spannuth, WA; Nick, AM; Jennnings, NB (2008). "Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer". Neoplasia (New York, N.Y.). 10 (11): 1259–67. PMC 2570602Freely accessible. PMID 18953435. 
  3. Delbaldo, C; Raymond, E; Vera, K; Hammershaimb, L; Kaucic, K; Lozahic, S; Marty, M; Faivre, S (2008). "Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors". Investigational new drugs. 26 (1): 35–43. doi:10.1007/s10637-007-9077-0. PMID 17876527.